Welcome to our dedicated page for Pluri news (Ticker: PLUR), a resource for investors and traders seeking the latest updates and insights on Pluri stock.
Pluri Inc. (PLUR) is a biotechnology company that regularly issues news about its cell-based platform, collaborations and corporate developments. The company describes itself as pioneering mass-scale cell expansion and biofarming, applying a patented 3D cell expansion system across regenerative medicine, foodtech, agtech, aesthetics and CDMO services. Its news flow reflects this multi-vertical strategy and the evolution of its collaborative network of ventures.
Investors and observers following Pluri’s news can expect updates on strategic partnerships and subsidiary activity in cultivated meat, cacao and coffee through entities such as Ever After Foods, Kokomodo and Coffeesai. Recent announcements have covered international collaborations in Asia, Europe, the United States and Latin America aimed at advancing cell-based food and agriculture production, as well as agreements with public bodies like the Instituto del Café de Chiapas in Mexico.
Pluri also publishes news on its healthcare and immunotherapy work, including patents for immune cell expansion technologies and developments in its placental-derived MAIT cell platform. Additional releases highlight the launch of new ventures such as Cellav Health and Aesthetics, collaborations in exosome-based skincare with Miss Universe Skincare, and CDMO contracts through PluriCDMO with biopharmaceutical partners like Remedy Cell.
Corporate and capital markets updates, such as shareholder letters, board and leadership changes, equity financings and governance matters, are also disclosed through Pluri’s news. Readers who monitor the PLUR news page can review this mix of scientific, commercial and corporate announcements to understand how the company is applying its 3D cell expansion platform and how its network of ventures and partnerships is progressing over time.
Pluri (NASDAQ, TASE: PLUR) announced completion of the first phase of its PluriCDMO program with Resbiomed on Jan 22, 2026. The initial phase covered process development and feasibility for scalable production of placenta-derived, collagen-rich biomaterials. Next phase will target process definition, reproducibility and manufacturing readiness, subject to mutually agreed scope and timelines. Pluri applied proprietary placenta-based processing and bioprocessing expertise to establish tissue extraction and processing protocols aimed at preserving and concentrating endogenous human collagen for regenerative-medicine applications.
Pluri (Nasdaq, TASE: PLUR) and Remedy Cell announced an expanded manufacturing collaboration on Dec 22, 2025. PluriCDMO completed implementation of Remedy Cell’s proprietary process in its GMP facility, provided GMP training and qualification, executed engineering runs to confirm process robustness and scalability, and manufactured several clinical-grade batches of Remedy Cell’s lead candidate for a planned Phase 1b clinical trial.
The companies will broaden the agreement so PluriCDMO continues providing manufacturing and process-development support as Remedy Cell advances clinical and pre-commercial programs, positioning PluriCDMO as a CDMO partner for complex cell-derived and cell-free biologics.
Pluri (Nasdaq, TASE: PLUR) appointed shareholder Alejandro Weinstein as Chairman on Dec 9, 2025, while prior Chairman Zami Aberman will transition to Vice Chairman. Weinstein’s ownership is expected to rise to approximately 30%, and he brings a track record including a prior company sale to Abbott for $2.9 billion.
Pluri entered a private placement where an entity beneficially owned by Weinstein will purchase 625,000 common shares plus warrants for an additional 625,000 shares at a combined purchase price of $4, generating gross proceeds of ~$2.5 million. Warrants exercise price is $4.25, exercisable immediately until June 30, 2026. Proceeds are for general working capital.
Pluri (NASDAQ, TASE: PLUR) announced multiple industry honors on Nov 13, 2025, highlighting progress in applying its proprietary 3D cell expansion platform to agriculture and food systems.
Key recognitions include Overall BioAgriculture Company of the Year from Biotech Breakthrough Awards, AgriNext’s award for Coffeesai Ltd. for sustainable cell‑based coffee production, MassChallenge Switzerland 2025 gold for Kokomodo Ltd., and a listing on Dun’s 100 Best HighTech Companies to work for 2025. Pluri also won Israel’s 2024 Egalitarian Employment Award (Large Company) and expects a government grant of 40,000 NIS.
Pluri (NASDAQ, TASE: PLUR) launched a wholly-owned subsidiary, Cellav Health and Aesthetics, to commercialize exosome-enhanced regenerative skincare using Pluri’s proprietary 3D cell expansion platform.
Pluri announced a commercial collaboration with Miss Universe Skincare to co-develop a line of cell-based skincare products, with the first product expected to launch in the first half of 2026 and be distributed via Miss Universe Skincare’s global platform. The collaboration will be presented during pre-gala activities of the 74th Miss Universe event in Thailand. Management describes the move as part of Pluri’s strategy to enter high-growth, revenue-generating beauty markets.
Pluri (NASDAQ, TASE: PLUR) announced on November 10, 2025 a series of international strategic collaborations across Asia, Europe and the U.S. through its subsidiaries Ever After Foods, Kokomodo and Coffeesai to advance cultivated meat, cultivated cacao and cell-based coffee.
Each collaboration is anchored by a collaborator-funded minimum-viable-product (MVP) / proof-of-concept to support scale-up validation, pre-commercial trials and pilot results, with near-term milestones focused on pilot readouts and expansion of collaborator programs in priority markets.
Pluri (NASDAQ/TASE: PLUR) subsidiary Coffeesai signed a collaboration with the Instituto del Café de Chiapas on Oct 8, 2025 to advance cell-based coffee manufacturing in Chiapas, Mexico. The agreement establishes a three-phase roadmap: cell line development, pilot-scale 3D bioreactor biofarming in Chiapas, and evaluation of commercial-scale manufacturing subject to definitive agreements and approvals. The partnership aims for non-dilutive license and technology-transfer revenues, royalty-bearing models and joint ventures to access the >$250B global coffee market. Coffeesai will begin Phase 1 immediately to validate cell lines, then deploy pilot-scale operations to test scalability and process robustness.
BrainStorm Cell Therapeutics (NASDAQ: BCLI) has signed a Letter of Intent with Minaris Advanced Therapies for manufacturing NurOwn®, its adult stem cell therapy for ALS treatment. The partnership will facilitate technology transfer and clinical trial manufacturing at Minaris' Allendale, New Jersey facility in preparation for BrainStorm's planned Phase 3b clinical trial.
This U.S.-based manufacturing collaboration complements BrainStorm's recent partnership with Pluri Inc. (Nasdaq: PLUR) in Israel, establishing a robust manufacturing network for NurOwn®. The strategic relationship aims to advance the clinical development of this therapy for ALS patients through a multicenter Phase 3b trial.
Pluri Inc. (PLUR) has completed the acquisition of approximately 71% stake in Kokomodo , a cultivated cacao AgFoodTech company, for $4.5 million paid in 976,139 Common Shares. The strategic acquisition combines Pluri's mass-scale cell production expertise with Kokomodo's cellular agriculture technology for creating climate-resilient cacao.
Kokomodo will continue operating independently as a Pluri subsidiary, maintaining its mission, team, and brand identity under CEO Tal Govrin's leadership. The acquisition aims to accelerate Kokomodo's production capabilities and global expansion while addressing sustainability challenges in the cacao industry.
The global cacao market, valued at $13.5 billion in 2023, is projected to grow at a CAGR of 8.2% to reach $23.5 billion by 2030.
FAQ
What is the current stock price of Pluri (PLUR)?
What is the market cap of Pluri (PLUR)?
